Effect of dietary eugenol on xenobiotic metabolism and mediation of UDP-glucuronosyltransferase and cytochrome P450 1A1 expression in rat liver

Reference

• Aggarwal BB, Kunnumakkara AB, Harikumar KB, Tharakan ST, Sung B, Anand P. 2008. Potential of spice-derived phytochemicals for cancer prevention. Planta Medica 74:1560–1569
   PubMed Web of Science ®Google Scholar
• Aggarwal BB, Shishodia S. 2006. Molecular targets of dietary agents for prevention and therapy of cancer. Biochem Pharmacol 71:1397–1421
   PubMed Web of Science ®Google Scholar
• Barry H, Cole SPC, Kuchler K, Higgins CF. 2003. ABC proteins: from bacteria to man. Academic Press
   Google Scholar
• Buetler TM, Gallagher EP, Wang C, Stahl DL, Hayes JD, Eaton DL. 1995. Induction of phase I and phase II drug-metabolizing enzyme mRNA, protein, and activity by BHA, ethoxyquin, and oltipraz. Toxicol Appl Pharmacol 135:45–57
   PubMed Web of Science ®Google Scholar
• Di Pietro G, Magno LA, Rios-Santos F. 2010. Glutathione S-transferases: an overview in cancer research. Expert Opin Drug Metab Toxicol 6:153–170
   PubMed Web of Science ®Google Scholar
• Ghosh R, Nadiminty N, Fitzpatrick JE, Alworth WL, Slaga TJ, Kumar AP. 2005. Eugenol causes melanoma growth suppression through inhibition of E2F1 transcriptional activity. J Biol Chem 280:5812–5819
   PubMed Web of Science ®Google Scholar
• Hediger MA, Romero MF, Peng JB, Rolfs A, Takanaga H, Bruford EA. 2004. The ABCs of solute carriers: physiological, pathological and therapeutic implications of human membrane transport proteins. Pflugers Arch 447:465–468
   PubMed Web of Science ®Google Scholar
• Hu R, Shen G, Yerramilli UR, Lin W, Xu C, Nair S, Kong AN. 2006. In vivo pharmacokinetics, activation of MAPK signaling and induction of phase II/III drug metabolizing enzymes/transporters by cancer chemopreventive compound BHA in the mice. Arch Pharm Res 29:911–920
   PubMed Web of Science ®Google Scholar
• Ikushiro S, Emi Y, Iyanagi T. 1997. Protein--protein interactions between UDP-glucuronosyltransferase isozymes in rat hepatic microsomes. Biochemistry 36:7154–7161
   PubMed Web of Science ®Google Scholar
• Iwano H, Yokota H, Ohgiya S, Yotumoto N, Yuasa A. 1997. A critical amino acid residue, asp446, in UDP-glucuronosyltransferase. Biochem J 325:587–591
   PubMed Web of Science ®Google Scholar
• Iyanagi T, Watanabe T, Uchiyama Y. 1989. The 3-methylcholanthrene-inducible UDP-glucuronosyltransferase deficiency in the hyperbilirubinemic rat (Gunn rat) is caused by a-1 frameshift mutation. J Biol Chem 264:21302–21307
   PubMed Web of Science ®Google Scholar
• Kamatou GP, Vermaak I, Viljoen AM. 2012. Eugenol – from the remote Maluku islands to the international market place: a review of a remarkable and versatile molecule. Molecules 17:6953–6981
   PubMed Web of Science ®Google Scholar
• Kawajiri K, Fujii-Kuriyama Y. 2007. Cytochrome P450 gene regulation and physiological functions mediated by the aryl hydrocarbon receptor. Arch Biochem Biophys 464:207–212
   PubMed Web of Science ®Google Scholar
• Ke S, Rabson AB, Germino JF, Gallo MA, Tian Y. 2001. Mechanism of suppression of cytochrome P-450 1A1 expression by tumor necrosis factor-alpha and lipopolysaccharide. J Biol Chem 276:39638–39644
   PubMed Web of Science ®Google Scholar
• Kim SS, Oh OJ, Min HY, Park EJ, Kim Y, Park HJ, Nam Han Y, Lee SK. 2003. Eugenol suppresses cyclooxygenase-2 expression in lipopolysaccharide-stimulated mouse macrophage RAW264.7 cells. Life Sci 73:337–348
   PubMed Web of Science ®Google Scholar
• Kong AN, Owuor E, Yu R, Hebbar V, Chen C, Hu R, Mandlekar S. 2001. Induction of xenobiotic enzymes by the MAP kinase pathway and the antioxidant or electrophile response element (ARE/EpRE). Drug Metab Rev 33:255–271
   PubMed Web of Science ®Google Scholar
• Mackenzie PI, Gregory PA, Gardner-Stephen DA, Lewinsky RH, Jorgensen BR, Nishiyama T, Xie W, Radominska-Pandya A. 2003. Regulation of UDP glucuronosyltransferase genes. Curr Drug Metab 4:249–257
   PubMed Web of Science ®Google Scholar
• Mackenzie PI, Owens IS, Burchell B, Bock KW, Bairoch A, Belanger A, Fournel-Gigleux S, et al. 1997. The UDP glycosyltransferase gene superfamily: recommended nomenclature update based on evolutionary divergence. Pharmacogenetics 7:255–269
   PubMedGoogle Scholar
• Maher J, Yamamoto M. 2010. The rise of antioxidant signaling – the evolution and hormetic actions of Nrf2. Toxicol Appl Pharmacol 244:4–15
   PubMed Web of Science ®Google Scholar
• Manikandan P, Murugan RS, Priyadarsini RV, Vinothini G, Nagini S. 2010. Eugenol induces apoptosis and inhibits invasion and angiogenesis in a rat model of gastric carcinogenesis induced by MNNG. Life Sci 86:936–941
   PubMed Web of Science ®Google Scholar
• Nebert DW, Dalton TP. 2006. The role of cytochrome P450 enzymes in endogenous signalling pathways and environmental carcinogenesis. Nat Rev Cancer 6:947–960
   PubMed Web of Science ®Google Scholar
• Nebert DW, Gonzalez FJ. 1987. P450 genes: structure, evolution, and regulation. Ann Rev Biochem 56:945–993
   PubMed Web of Science ®Google Scholar
• Nelson DR, Kamataki T, Waxman DJ, Guengerich FP, Estabrook RW, Feyereisen R, Gonzalez FJ, et al. 1993. The P450 superfamily: update on new sequences, gene mapping, accession numbers, early trivial names of enzymes, and nomenclature. DNA Cell Biol 12:1–51
   PubMed Web of Science ®Google Scholar
• Park KR, Lee JH, Choi C, Liu KH, Seog DH, Kim YH, Kim DE, et al. 2007. Suppression of interleukin-2 gene expression by isoeugenol is mediated through down-regulation of NF-AT and NF-kappaB. Int Immunopharmacol 7:1251–1258
   PubMed Web of Science ®Google Scholar
• Pisano M, Pagnan G, Loi M, Mura ME, Tilocca MG, Palmieri G, Fabbri D, et al. 2007. Antiproliferative and pro-apoptotic activity of eugenol-related biphenyls on malignant melanoma cells. Mol Cancer 6:8--19
   PubMed Web of Science ®Google Scholar
• Pollenz RS. 2002. The mechanism of AH receptor protein down-regulation (degradation) and its impact on AH receptor-mediated gene regulation. Chem Biol Interact 141:41–61
   PubMed Web of Science ®Google Scholar
• Rushmore TH, Kong AN. 2002. Pharmacogenomics, regulation and signaling pathways of phase I and II drug metabolizing enzymes. Curr Drug Metab 3:481–490
   PubMed Web of Science ®Google Scholar
• Xu C, Li CY, Kong AN. 2005. Induction of phase I, II and III drug metabolism/transport by xenobiotics. Arch Pharm Res 28:249–268
   PubMed Web of Science ®Google Scholar
• Yokota H, Hashimoto H, Motoya M, Yuasa A. 1988. Enhancement of UDP-glucuronyltransferase, UDP-glucose dehydrogenase, and glutathione S-transferase activities in rat liver by dietary administration of eugenol. Biochem Pharmacol 37:799–802
   PubMedGoogle Scholar
• Yokota H, Hoshino J, Yuasa A. 1986. Suppressed mutagenicity of benzo[a]pyrene by the liver S9 fraction and microsomes from eugenol-treated rats. Mutat Res 172:231–236
   PubMedGoogle Scholar
• Yoo CB, Han KT, Cho KS, Ha J, Park HJ, Nam JH, Kil UH, Lee KT. 2005. Eugenol isolated from the essential oil of Eugenia caryophyllata induces a reactive oxygen species-mediated apoptosis in HL-60 human promyelocytic leukemia cells. Cancer Lett 225:41–52
   PubMed Web of Science ®Google Scholar
• Report. 1983. Carcinogenesis studies of eugenol in F344/N rats and B6C3F1 mice. National Toxicology Program Technical Report Series, No. 223
   Google Scholar